I subscribe to a number of journals.

New England Journal of Medicine

The War-Zone Mentality — Mental Health Effects of Gun Violence in U.S. Children and Adolescents
New England Journal of Medicine, Volume 387, Issue 13, Page 1149-1151, September 2022.
>> Read more

Intradermal Vaccination for Monkeypox — Benefits for Individual and Public Health
New England Journal of Medicine, Volume 387, Issue 13, Page 1151-1153, September 2022.
>> Read more

Product Hopping in the Drug Industry — Lessons from Albuterol
New England Journal of Medicine, Volume 387, Issue 13, Page 1153-1156, September 2022.
>> Read more

A Hidden Crisis
New England Journal of Medicine, Volume 387, Issue 13, Page 1157-1159, September 2022.
>> Read more


Heartbeat: knowledge gaps for non-bacterial thrombotic endocarditis
Non-bacterial thrombotic endocarditis (NBTE) contributes to adverse outcomes in patients with systemic inflammatory conditions, antiphospholipid syndrome or advanced malignancy (figure 1). Diagnosis is challenging and there is little data to guide prevention of adverse events, particularly stroke. In this issue of Heart, Quintero-Martinez and colleagues1 report the clinical characteristics and outcomes in 48 adults with NBTE identified at the Mayo Clinic over a 7 year period. Most patients (75%) were women with a mean age of 60 years and most cases were associated with malignancy (52%) or a systemic inflammatory disease (38%). Adverse events included moderate-severe valve regurgitation (54%), systemic embolic events (54%) and a 1 year mortality of 33%, often related to the underlying malignancy. Figure 1 Transoesophageal echocardiographic images of non-bacterial thrombotic endocarditis. (A) Zoomed mid-oesophageal four-chamber view in systole showing a thickened mitral valve with stuck-on kissing lesions on the leaflet tips...
>> Read more

Towards improving clinical and patient-centred outcomes in patients with light chain amyloidosis
Systemic light chain (AL) amyloidosis is an uncommon disease that results from organ deposition of light chain immunoglobulins produced by a plasma cell neoplasm. Cardiac involvement with the disease is the primary determinant of prognosis, and the cardiac biomarkers N-terminal pro-brain natriuretic peptide (NT-proBNP) and troponin have formed the backbone for prognostication in AL amyloidosis over the last decade. Accurate assessment of baseline risk and cardiac treatment response are critical to guide treatment selection and intensity of therapeutic monitoring. In this issue of Heart, Cohen et al1 evaluated the 6 min walk test (6MWT) as a prognostic indicator in patients with AL amyloidosis. Seven hundred and ninety-nine patients with newly diagnosed AL amyloidosis seen at the UK National Amyloidosis Centre were prospectively enrolled in an observational study and followed for a median of 32 months. The 6 min walk distance (6MWD) was assessed at baseline and at 6 months,...
>> Read more


Heart Rhythm